It was supposed to be a $10 billion idea, one that would help wean the world off its opioid dependence and give the drug industry a bounty of lucrative new products.
But the bottom fell out for a new class of pain medicines, called NGF inhibitors, when patients in clinical trials starting inexplicably blowing out their joints. The Food and Drug Administration put a halt to further studies in 2010, and a bunch of once-transformational drugs suddenly looked like costly scientific mistakes.
Now, after years of research and perseverance, a handful of biopharma companies believe they’ve found a safe way to relieve pain with NGF treatments, pressing through late-stage trials that will determine whether the old drugs can finally pass FDA muster and provide a much-needed alternative to opioids.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect